Normal view

Received — 13 September 2026 ⏭ Nature Medicine

Nature Medicine
Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial Omar Nadeem · David M. Cordas dos Santos · Sophie Magidson · Jeffrey Matous · Eva Medvedova · Elizabeth O’Donnell · Robert A. Redd · Yuxin Liu · Shonali Midha · Adam S. Sperling · Frances Arters · Christine Davie · Caroline Ricciardi · Rosa Toenges · Nayda Bidikian · Subear Hussein · Jean-Baptiste Alberge · Sungjae Kim · Lorena Pantano-Rubino · Francesco Corrado · Hannah Ashton · Daniel Addonizio · Siham Mohamed · Ashlee Sturtevant · Marjorie Marto · Amy Bergeron · Francesco Malfona · Kevin Panaro · Paul G. Richardson · Jerome Ritz · Lorenzo Trippa · Irene M. Ghobrial
Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04642-wIn the randomized phase 2 ImmunoPRISM trial, patients with high-risk smoldering multiple myeloma (MM) showed higher rates of complete clinical responses in response to treatment with teclistamab compared with lenalidomide–dexamethasone, although longer follow-up is required to determine durable prevention of progression to MM.
11 September 2026 at 08:00

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

By: Omar Nadeem · David M. Cordas dos Santos · Sophie Magidson · Jeffrey Matous · Eva Medvedova · Elizabeth O’Donnell · Robert A. Redd · Yuxin Liu · Shonali Midha · Adam S. Sperling · Frances Arters · Christine Davie · Caroline Ricciardi · Rosa Toenges · Nayda Bidikian · Subear Hussein · Jean-Baptiste Alberge · Sungjae Kim · Lorena Pantano-Rubino · Francesco Corrado · Hannah Ashton · Daniel Addonizio · Siham Mohamed · Ashlee Sturtevant · Marjorie Marto · Amy Bergeron · Francesco Malfona · Kevin Panaro · Paul G. Richardson · Jerome Ritz · Lorenzo Trippa · Irene M. Ghobrial

11 September 2026 at 08:00

Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04642-w

In the randomized phase 2 ImmunoPRISM trial, patients with high-risk smoldering multiple myeloma (MM) showed higher rates of complete clinical responses in response to treatment with teclistamab compared with lenalidomide–dexamethasone, although longer follow-up is required to determine durable prevention of progression to MM.